Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis

Multiple Myeloma (MM)
Do you want to read an article? Please log in or register.